The standard treatment for bowel cancer has been to have surgery to remove the tumour, usually followed by chemotherapy. However, FOxTROT 1 research showed that giving chemotherapy before surgery was safe and reduced the chance of the cancer coming back. This means that giving chemotherapy before surgery (neoadjuvant chemotherapy) is now a standard treatment option for some bowel cancer patients.
Upon joining FOxTROT 3, patients will be randomly allocated either to receive the FOxTROT 3 approach – 6 weeks of ‘intensified’ neoadjuvant chemotherapy with three chemotherapy medicines) before surgery or ‘non-intensified’ neoadjuvant chemotherapy (two chemotherapy medicines) before surgery. Both sets of patients will also receive chemotherapy after surgery.
UK Hospitals Taking Part in the Trials
Below is a map of the UK hospitals taking part in the trials.
FOxTROT 3 Patient Information Sheet
For more detail on what the research might involve for you, please read the FOxTROT 3 Patient Information Sheet or speak to the team treating you.